|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ABHD13 |
Gene summary for ABHD13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ABHD13 | Gene ID | 84945 |
| Gene name | abhydrolase domain containing 13 | |
| Gene Alias | BEM46L1 | |
| Cytomap | 13q33.3 | |
| Gene Type | protein-coding | GO ID | GO:0002084 | UniProtAcc | A0A024RDX1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84945 | ABHD13 | LZE4T | Human | Esophagus | ESCC | 3.15e-03 | 9.20e-02 | 0.0811 |
| 84945 | ABHD13 | LZE7T | Human | Esophagus | ESCC | 4.72e-03 | 2.31e-01 | 0.0667 |
| 84945 | ABHD13 | LZE8T | Human | Esophagus | ESCC | 5.00e-05 | 2.36e-01 | 0.067 |
| 84945 | ABHD13 | LZE20T | Human | Esophagus | ESCC | 4.76e-03 | 1.27e-01 | 0.0662 |
| 84945 | ABHD13 | LZE24T | Human | Esophagus | ESCC | 1.19e-10 | 2.34e-01 | 0.0596 |
| 84945 | ABHD13 | LZE6T | Human | Esophagus | ESCC | 3.49e-03 | 1.50e-01 | 0.0845 |
| 84945 | ABHD13 | P1T-E | Human | Esophagus | ESCC | 4.36e-02 | 9.48e-02 | 0.0875 |
| 84945 | ABHD13 | P2T-E | Human | Esophagus | ESCC | 1.71e-13 | 2.26e-01 | 0.1177 |
| 84945 | ABHD13 | P4T-E | Human | Esophagus | ESCC | 1.32e-09 | 2.52e-01 | 0.1323 |
| 84945 | ABHD13 | P5T-E | Human | Esophagus | ESCC | 1.22e-02 | 6.95e-02 | 0.1327 |
| 84945 | ABHD13 | P8T-E | Human | Esophagus | ESCC | 6.68e-26 | 3.89e-01 | 0.0889 |
| 84945 | ABHD13 | P9T-E | Human | Esophagus | ESCC | 5.57e-07 | 2.20e-01 | 0.1131 |
| 84945 | ABHD13 | P10T-E | Human | Esophagus | ESCC | 1.85e-16 | 2.70e-01 | 0.116 |
| 84945 | ABHD13 | P11T-E | Human | Esophagus | ESCC | 7.52e-11 | 5.26e-01 | 0.1426 |
| 84945 | ABHD13 | P12T-E | Human | Esophagus | ESCC | 2.46e-16 | 3.39e-01 | 0.1122 |
| 84945 | ABHD13 | P15T-E | Human | Esophagus | ESCC | 8.24e-16 | 3.01e-01 | 0.1149 |
| 84945 | ABHD13 | P16T-E | Human | Esophagus | ESCC | 4.17e-23 | 2.85e-01 | 0.1153 |
| 84945 | ABHD13 | P17T-E | Human | Esophagus | ESCC | 4.29e-02 | 2.14e-01 | 0.1278 |
| 84945 | ABHD13 | P21T-E | Human | Esophagus | ESCC | 1.68e-06 | 1.56e-01 | 0.1617 |
| 84945 | ABHD13 | P22T-E | Human | Esophagus | ESCC | 1.85e-06 | 8.68e-02 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00356015 | Esophagus | ESCC | protein deacylation | 79/8552 | 112/18723 | 8.30e-08 | 1.42e-06 | 79 |
| GO:00987325 | Esophagus | ESCC | macromolecule deacylation | 80/8552 | 116/18723 | 3.19e-07 | 4.50e-06 | 80 |
| GO:00421573 | Esophagus | ESCC | lipoprotein metabolic process | 86/8552 | 135/18723 | 1.78e-05 | 1.57e-04 | 86 |
| GO:00020842 | Esophagus | ESCC | protein depalmitoylation | 9/8552 | 10/18723 | 5.09e-03 | 1.92e-02 | 9 |
| GO:00421593 | Esophagus | ESCC | lipoprotein catabolic process | 12/8552 | 15/18723 | 7.31e-03 | 2.63e-02 | 12 |
| GO:00356014 | Oral cavity | OSCC | protein deacylation | 74/7305 | 112/18723 | 5.88e-09 | 1.26e-07 | 74 |
| GO:00987324 | Oral cavity | OSCC | macromolecule deacylation | 74/7305 | 116/18723 | 5.52e-08 | 1.01e-06 | 74 |
| GO:00421572 | Oral cavity | OSCC | lipoprotein metabolic process | 77/7305 | 135/18723 | 1.61e-05 | 1.60e-04 | 77 |
| GO:00421592 | Oral cavity | OSCC | lipoprotein catabolic process | 11/7305 | 15/18723 | 7.49e-03 | 2.75e-02 | 11 |
| GO:0002084 | Oral cavity | OSCC | protein depalmitoylation | 8/7305 | 10/18723 | 1.03e-02 | 3.53e-02 | 8 |
| GO:004215711 | Oral cavity | LP | lipoprotein metabolic process | 57/4623 | 135/18723 | 5.59e-06 | 1.11e-04 | 57 |
| GO:003560113 | Oral cavity | LP | protein deacylation | 48/4623 | 112/18723 | 1.85e-05 | 3.14e-04 | 48 |
| GO:009873212 | Oral cavity | LP | macromolecule deacylation | 48/4623 | 116/18723 | 5.51e-05 | 7.58e-04 | 48 |
| GO:00421591 | Oral cavity | LP | lipoprotein catabolic process | 10/4623 | 15/18723 | 7.11e-04 | 6.37e-03 | 10 |
| GO:00020841 | Oral cavity | LP | protein depalmitoylation | 7/4623 | 10/18723 | 3.24e-03 | 2.18e-02 | 7 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ABHD13 | SNV | Missense_Mutation | novel | c.962N>T | p.Ser321Ile | p.S321I | Q7L211 | protein_coding | tolerated(0.22) | benign(0.11) | TCGA-A7-A3IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| ABHD13 | SNV | Missense_Mutation | c.299N>G | p.Asn100Ser | p.N100S | Q7L211 | protein_coding | tolerated(0.1) | benign(0.053) | TCGA-BH-A1EX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ABHD13 | SNV | Missense_Mutation | c.193N>T | p.Leu65Phe | p.L65F | Q7L211 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| ABHD13 | SNV | Missense_Mutation | rs775164089 | c.706N>T | p.Arg236Cys | p.R236C | Q7L211 | protein_coding | deleterious(0.01) | possibly_damaging(0.583) | TCGA-E2-A1L9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| ABHD13 | SNV | Missense_Mutation | c.547N>A | p.Asp183Asn | p.D183N | Q7L211 | protein_coding | tolerated(0.68) | possibly_damaging(0.669) | TCGA-E9-A1NH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| ABHD13 | SNV | Missense_Mutation | c.533C>G | p.Thr178Ser | p.T178S | Q7L211 | protein_coding | tolerated(1) | benign(0.055) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| ABHD13 | SNV | Missense_Mutation | novel | c.184G>A | p.Asp62Asn | p.D62N | Q7L211 | protein_coding | deleterious(0) | benign(0.348) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ABHD13 | SNV | Missense_Mutation | c.112C>T | p.His38Tyr | p.H38Y | Q7L211 | protein_coding | tolerated(0.77) | benign(0.006) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ABHD13 | SNV | Missense_Mutation | c.825N>C | p.Met275Ile | p.M275I | Q7L211 | protein_coding | deleterious(0.01) | probably_damaging(0.968) | TCGA-FU-A3NI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ABHD13 | SNV | Missense_Mutation | novel | c.715N>T | p.Pro239Ser | p.P239S | Q7L211 | protein_coding | deleterious(0) | possibly_damaging(0.574) | TCGA-MA-AA3X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |